Nrx pharmaceuticals, inc. (nasdaq: nrxp) announces receipt of positive nasdaq listing determination

Radnor, pa. , jan. 17, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx" or the "company"), a clinical-stage biopharmaceutical company developing therapies for suicidal depression, chronic pain, and ptsd, today announced that on january 16, 2024, the company was notified by the nasdaq stock market llc ("nasdaq") that the nasdaq hearings panel (the "panel") granted the company's request for the transfer of its listing to the nasdaq capital market, subject to the company evidencing compliance with all applicable criteria for continued listing on the capital market tier, including the $35 million in market value of listed securities (mvls) and the $1.00 bid price requirements.
NRXP Ratings Summary
NRXP Quant Ranking